Retatrutide is not licensed as a medicine in any jurisdiction. That has not stopped a counterfeit market for it forming in the UK faster than the compound's own regulatory pathway — a development the BBC documented on 6 September 2026, and one that sits at the centre of the MHRA's largest-ever enforcement actions against illegal weight-loss medicines.
What the BBC investigation found
The BBC reported vials purporting to contain retatrutide — sold under the shorthand 'reta' — being offered in UK gyms, nail and beauty salons, hairdressers, on social media, and by street sellers. Experts told the BBC it was among the first times they had seen counterfeit versions of an experimental drug, still in clinical trials, become so widely available. The MHRA confirmed it has carried out raids and made several seizures of 'products claiming to contain retatrutide' over the past year, and says it is working to disrupt illegal importation and distribution.
Why retatrutide is not a lawful UK medicine
Retatrutide is an investigational triple agonist acting at the GIP, GLP-1 and glucagon receptors. It has no UK marketing authorisation from the MHRA and, as the BBC noted, has not been approved for human use by any regulator. Its Phase 3 programme remains the subject of ongoing read-outs; positive trial results are not a licence, and unlicensed status carries legal consequences for anyone who manufactures, imports, sells or supplies it in the UK. The GLP-1 and dual GIP/GLP-1 peptides that are licensed here — semaglutide, tirzepatide and liraglutide — are prescription-only medicines, so neither a licence nor a prescription exists for any black-market retatrutide product.
The enforcement record
On 28 May 2026 officers from the MHRA's Criminal Enforcement Unit, supported by Northamptonshire Police, raided a country estate near Northampton and recovered around 12,000 doses of unlicensed weight-loss medicines — the largest seizure of such products the agency has made. Two men, both aged 29, were arrested on suspicion of offences under the Human Medicines Regulations 2012. The property is believed to have been used to manufacture, assemble and distribute unlicensed weight-loss medicines, including retatrutide and tirzepatide, as well as peptide products. The raid followed earlier actions in Lincolnshire and Nottinghamshire in February 2026, part of the same investigation into an organised criminal network, and an October 2025 seizure of more than 2,000 unlicensed retatrutide and tirzepatide pens from a Northampton warehouse.
The Alluvi Healthcare brand
A second BBC investigation, published in September 2026, reported that more than £200,000 had been frozen across three bank accounts linked to Alluvi Healthcare, following an MHRA application to Northampton Magistrates' Court under the Proceeds of Crime Act. UK Intellectual Property Office records cited by the BBC show the Alluvi Healthcare name and logo were registered as a trademark in April 2026. The BBC reported four MHRA raids in nine months that uncovered thousands of doses of Alluvi-branded weight-loss drugs at sites in Northampton, Sleaford and Grantham. Andy Morling, head of the MHRA's Criminal Enforcement Unit, told the BBC the investigation was the first time he had seen suspected criminals 'creating their own brand' rather than producing counterfeits of established products.
The manufacturer's position
Eli Lilly, which has developed retatrutide for nearly a decade, says it has reported more than 14,000 websites, advertisements and social-media posts it alleges were illegally marketing the compound, and that it continues to work with law enforcement and regulators to combat black-market drugs. A company spokesperson told the BBC that any retatrutide available online is 'unapproved, unverified and simply not worth the risk'. The BBC also reported that some users of counterfeit products described adverse effects including brain fog, nausea, diarrhoea, loss of libido and anhedonia. Those reports concern falsified products of unknown composition; they are not evidence about the investigational drug itself.
What this means for research-context readers
Under the Human Medicines Regulations 2012, selling or supplying an unlicensed medicinal product in the UK is a criminal offence, and the Medicines Act 1968 provides the framework within which the MHRA acts. A 'research use only' label on a grey-market vial does not create a lawful supply route: it does not authorise import, sale, supply or human use, and it does not make the contents verifiable. Products seized in these operations were not produced in licensed laboratories, so their identity, sterility, concentration and dose cannot be confirmed. Peptide Data's position is unchanged — this library is a research reference. It documents what the literature and the regulators actually say; it does not provide sourcing, consumption or dosing guidance, and it does not endorse any unlicensed supplier.
The compound, in context
Retatrutide remains one of the most closely watched investigational peptides in the metabolic field, with Phase 3 data reported across obesity, type 2 diabetes and cardiovascular populations. None of that changes its UK legal position: it is an unapproved medicine, and the market that has grown around it is a criminal one. The enforcement picture above is the clearest illustration yet of why the gap between trial promise and lawful supply is where the greatest risk sits.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.